TY - JOUR
T1 - Cardiac Arrhythmias in Critically Ill Patients With COVID-19
T2 - A Brief Review
AU - Karamchandani, Kunal
AU - Quintili, Ashley
AU - Landis, Terra
AU - Bose, Somnath
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/12
Y1 - 2021/12
N2 - Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2, is now a global pandemic affecting more than 12 million patients across 188 countries. A significant proportion of these patients require admission to intensive care units for acute hypoxic respiratory failure and are at an increased risk of developing cardiac arrhythmias. The presence of underlying comorbidities, pathophysiologic changes imposed by the disease, and concomitant polypharmacy, increase the likelihood of life-threatening arrhythmias in these patients. Supraventricular, as well as ventricular arrhythmias, are common and are associated with significant morbidity and mortality. It is important to understand the interplay of various causal factors while instituting strategies to mitigate the impact of modifiable risk factors. Furthermore, avoidance and early recognition of drug interactions, along with prompt treatment, might help improve outcomes in this vulnerable patient population.
AB - Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2, is now a global pandemic affecting more than 12 million patients across 188 countries. A significant proportion of these patients require admission to intensive care units for acute hypoxic respiratory failure and are at an increased risk of developing cardiac arrhythmias. The presence of underlying comorbidities, pathophysiologic changes imposed by the disease, and concomitant polypharmacy, increase the likelihood of life-threatening arrhythmias in these patients. Supraventricular, as well as ventricular arrhythmias, are common and are associated with significant morbidity and mortality. It is important to understand the interplay of various causal factors while instituting strategies to mitigate the impact of modifiable risk factors. Furthermore, avoidance and early recognition of drug interactions, along with prompt treatment, might help improve outcomes in this vulnerable patient population.
UR - http://www.scopus.com/inward/record.url?scp=85090061971&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090061971&partnerID=8YFLogxK
U2 - 10.1053/j.jvca.2020.08.013
DO - 10.1053/j.jvca.2020.08.013
M3 - Review article
C2 - 32888796
AN - SCOPUS:85090061971
SN - 1053-0770
VL - 35
SP - 3789
EP - 3796
JO - Journal of cardiothoracic and vascular anesthesia
JF - Journal of cardiothoracic and vascular anesthesia
IS - 12
ER -